Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

Launched by JEREMY RUDNICK, M.D · Apr 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with recurrent glioblastoma, a type of brain cancer that comes back after initial treatment. The researchers want to see if using activated T cells—specialized immune cells from the patient's own body—can help fight the cancer safely. They will look at how many side effects patients experience and how effective the treatment is in improving survival and quality of life.

To participate in this study, potential patients need to have recurrent glioblastoma that has been fully removed through surgery and must have specific markers called HLA-A1 or HLA-A2. Unfortunately, individuals with certain health conditions, such as significant heart or lung diseases, or those with infections that require treatment, will not be eligible. If you join the study, you can expect close monitoring by the medical team to ensure your safety and to gather information on how well the treatment works. This trial is currently not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Recurrent glioblastoma
• • HLA-A1 and HLA-A2 positive
• • Complete resection of tumor
• Exclusion Criteria:
• • Clinically significant pulmonary, cardiac or other systemic disease
• • Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed.
• • Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition.
• • Known history of Hepatitis B or Hepatitis C
• • Allergy to Dimethyl sulfoxide (DMSO)
• • Allergy to gentamicin